The ability of DI-591 to induce robust upregulation of NRF2, coupled with its lack of cytotoxicity, suggests that DI-591 and its analogs should be evaluated as potential therapeutic agents for the treatment of multiple sclerosis and other human diseases in which strong upregulation of NRF2 may be beneficial. The gene discussed is NFE2L2; the disease is multiple sclerosis.